Trevi Therapeutics (TRVI) Tops Q1 EPS by 1c

Trevi Therapeutics (NASDAQ: TRVI) reported Q1 EPS of ($0.06), $0.01 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Jack Henry (JKHY) Tops Q4 EPS by 13c
• EXL closes $1 billion credit facility, up from $600 million